Extended half-life factor IX prophylaxis up to every 21 days in hemophilia B: a longitudinal analysis of the efficacy and safety in selected adult patients

BACKGROUND: Extended half-life factor IX (FIX) products have revolutionized prophylactic treatment for patients with hemophilia B as patients maintain protective FIX levels with minimal occurrence of spontaneous bleeding. rIX-FP is an extended half-life FIX product that allows prolonged dosing inter...

Descripción completa

Detalles Bibliográficos
Autores principales: Pabinger, Ingrid, Lissitchkov, Toshko, Nagao, Asuza, Lepatan, Lynda Mae, Li, Yanyan, Seifert, Wilfried, Mancuso, Maria Elisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394546/
https://www.ncbi.nlm.nih.gov/pubmed/37538501
http://dx.doi.org/10.1016/j.rpth.2023.100195

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394546/
https://www.ncbi.nlm.nih.gov/pubmed/37538501
http://dx.doi.org/10.1016/j.rpth.2023.100195

Ejemplares similares